Wolfgang Schuehly

Dr. Wolfgang Schuehly

Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl-Franzens-University Graz, Universitätsplatz 4, 8010 Graz, Austria

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2011 in Journal of Natural Products
Verified
Journal Article
Closed access
MGM. Salomé Gachet
M. Salomé Gachet
OKOlaf Kunert
Olaf Kunert
MKMarcel Kaiser
Marcel Kaiser
RBReto Brun
Reto Brun
MZMartin Zehl
Martin Zehl
WSWolfgang Schuehly
Wolfgang Schuehly

1 July 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
WSWolfgang Schuehly
Wolfgang Schuehly
AHAntje Hüfner
Antje Hüfner
EPEva-Maria Pferschy-Wenzig
Eva-Maria Pferschy-Wenzig
EPElke Prettner
Elke Prettner
MAMichael Adams
Michael Adams
Rudolf BauerRudolf Bauer
Rudolf Bauer

13 February 2009 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
WSWolfgang Schuehly
Wolfgang Schuehly
SKS. I. Khan
S. I. Khan
NFN. H. Fischer
N. H. Fischer

22 March 2010 in Journal of Natural Products
Verified
Journal Article
Closed access
MGM. Salomé Gachet
M. Salomé Gachet
OKOlaf Kunert
Olaf Kunert
MKMarcel Kaiser
Marcel Kaiser
RBReto Brun
Reto Brun
RMRicardo A. Muñoz
Ricardo A. Muñoz
WSWolfgang Schuehly
Wolfgang Schuehly

20 August 2009 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
OKOlaf Kunert
Olaf Kunert
GSGandhe Sreekanth
Gandhe Sreekanth
GBGummadi Sreedhar Babu
Gummadi Sreedhar Babu
BRBelvotagi Venkat Rao Adavi Rao
Belvotagi Venkat Rao Adavi Rao
MRMarupaka Radhakishan
Marupaka Radhakishan
WSWolfgang Schuehly
Wolfgang Schuehly

13 May 2015 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
ACAndrea Chicca
Andrea Chicca
MGMaria Salomé Gachet
Maria Salomé Gachet
VPVanessa Petrucci
Vanessa Petrucci
WSWolfgang Schuehly
Wolfgang Schuehly
RCRoch-Philippe Charles
Roch-Philippe Charles
Jürg GertschJürg Gertsch
Jürg Gertsch
4′-O-methylhonokiol (MH) is a natural product showing anti-inflammatory, anti-osteoclastogenic, and neuroprotective effects. MH was reported to modulate cannabinoid CB2 receptors as an inverse agonist for cAMP production and an agonist for intracellular [Ca2+]. It was recently shown that MH inhibits cAMP formation via CB2 receptors. In this study, the exact modulation of MH on CB2 receptor activity was elucidated and its endocannabinoid substrate-specific inhibition (SSI) of cyclooxygenase-2 (COX-2) and CNS bioavailability are described for the first time. CB2 receptor modulation ([35S]GTPγS, cAMP, and β-arrestin) by MH was measured in hCB2-transfected CHO-K1 cells and native conditions (HL60 cells and mouse spleen). The COX-2 SSI was investigated in RAW264.7 cells and in Swiss albino mice by targeted metabolomics using LC-MS/MS. MH is a CB2 receptor agonist and a potent COX-2 SSI. It induced partial agonism in both the [35S]GTPγS binding and β-arrestin recruitment assays while being a full agonist in the cAMP pathway. MH selectively inhibited PGE2 glycerol ester formation (over PGE2) in RAW264.7 cells and significantly increased the levels of 2-AG in mouse brain in a dose-dependent manner (3 to 20 mg kg−1) without affecting other metabolites. After 7 h from intraperitoneal (i.p.) injection, MH was quantified in significant amounts in the brain (corresponding to 200 to 300 nM). LC-MS/MS quantification shows that MH is bioavailable to the brain and under condition of inflammation exerts significant indirect effects on 2-AG levels. The biphenyl scaffold might serve as valuable source of dual CB2 receptor modulators and COX-2 SSIs as demonstrated by additional MH analogs that show similar effects. The combination of CB2 agonism and COX-2 SSI offers a yet unexplored polypharmacology with expected synergistic effects in neuroinflammatory diseases, thus providing a rationale for the diverse neuroprotective effects reported for MH in animal models.